


Attorney Docket No. 0/98414 US

In the Claims

Please amend the claims as follows:

D1
2. (Twice Amended) The steroid compound according to claim 1, wherein R₁₁ is selected from the following group of side-chain structures:




wherein X is CH₂, CH-alkyl or C(alkyl)₂, R₁ is H, alkyl, C₃-C₇ cycloalkyl or together with X forms a C₃-C₇ ring system, R₂ is H, alkyl or C₃-C₇ cycloalkyl, R₃ and R₄ each independently are H, alkyl or C₃-C₇ cycloalkyl, unsubstituted or substituted with halogen or CN, n is an integer of from 0-9, m is an integer of from 1-5.

Please add the following claim:

D2
--8. A method of inducing ER α agonist activity and ER β antagonist activity in a patient in need thereof, comprising:

administering an effective amount of a steroid compound satisfying the following structural formula:

Attorney Docket No. 0/98414 US



formula I

2
D
cont

wherein:

one of X and Y is OH, the other being H;

R₃ is H or COR'₃, with R'₃ being alkyl or aryl;


R₇, R₁₆, and R₁₇ each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl;

R₁₁ is a hydrocarbon group, which may be linear or branched, comprising one single linear chain having a length of from 5 to 9 carbon atoms as the longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated.

9. A pharmaceutical composition having ER α agonist activity and having ER β antagonist activity, comprising:

a steroid compound satisfying the following structural formula:

Attorney Docket No. O/98414 US



formula I

wherein:

one of X and Y is OH, the other being H;

R₃ is H or COR'₃, with R'₃ being alkyl or aryl;

R₇, R₁₆, and R₁₇ each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl; R₁₁ is a hydrocarbon group, which may be linear or branched, comprising one single linear chain having a length of from 5 to 9 carbon atoms as the longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated, and

a pharmaceutical acceptable auxiliary.

10. The pharmaceutical composition according to claim 9, wherein R₁₁ is selected from the following group of side-chain structures:

